scholarly journals Hormone receptor status may impact the survival benefit of surgery in stage IV breast cancer: a population-based study

Oncotarget ◽  
2016 ◽  
Vol 7 (43) ◽  
pp. 70991-71000 ◽  
Author(s):  
Yinuo Tan ◽  
Xiaofen Li ◽  
Haiyan Chen ◽  
Yeting Hu ◽  
Mengjie Jiang ◽  
...  
2004 ◽  
Vol 91 (7) ◽  
pp. 1263-1268 ◽  
Author(s):  
C Allemani ◽  
M Sant ◽  
F Berrino ◽  
T Aareleid ◽  
G Chaplain ◽  
...  

2019 ◽  
Vol 8 (10) ◽  
pp. 4906-4917 ◽  
Author(s):  
Zhen Zhai ◽  
Fang Zhang ◽  
Yi Zheng ◽  
Linghui Zhou ◽  
Tian Tian ◽  
...  

2018 ◽  
Vol 18 (1) ◽  
pp. e97-e105 ◽  
Author(s):  
Wei Chen ◽  
Ying Huang ◽  
Gary D. Lewis ◽  
Sean S. Szeja ◽  
Sandra S. Hatch ◽  
...  

Nutrients ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 994
Author(s):  
Facundo Vitelli-Storelli ◽  
Raul Zamora-Ros ◽  
Antonio J. Molina ◽  
Tania Fernández-Villa ◽  
Adela Castelló ◽  
...  

There is limited evidence of phenolic compounds acting as protective agents on several cancer types, including breast cancer (BC). Nevertheless, some polyphenol classes have not been investigated and there is a lack of studies assessing the effect on menopausal status and hormone receptor status as influenced by these compounds. The objective of this study is to evaluate the association between the intake of all polyphenol classes in relation to the BC risk by menopausal and hormone receptor status. We used data from a population-based multi-case-control study (MCC-Spain) including 1472 BC cases and 1577 controls from 12 different regions of Spain. The odds ratios (ORs) with 95% CI were calculated using logistic regression of mixed effects by quartiles and log2 of polyphenol intakes (adjusted for the residual method) of overall BC, menopausal and receptor status. No associations were found between total intake of polyphenols and BC risk. However, inverse associations were found between stilbenes and all BC risk (ORQ4 vs. Q1: 0.70, 95%CI: 0.56–0.89, Ptrend = 0.001), the consumption of hydroxybenzaldehydes (ORQ4 vs. Q1: 0.75, 95%CI: 0.59–0.93, Ptrend = 0.012) and hydroxycoumarins (ORQ4 vs. Q1: 0.73, 95%CI: 0.57–0.93; Ptrend = 0.005) were also inversely associated. The intake of stilbenes, hydroxybenzaldehydes and hydroxycoumarins can contribute to BC reduction risk on all menopausal and receptor statuses.


Sign in / Sign up

Export Citation Format

Share Document